{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T14:34:47Z","timestamp":1773066887065,"version":"3.50.1"},"reference-count":39,"publisher":"Japanese Society of Internal Medicine","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2015]]},"DOI":"10.2169\/internalmedicine.54.4935","type":"journal-article","created":{"date-parts":[[2015,10,14]],"date-time":"2015-10-14T22:22:49Z","timestamp":1444861369000},"page":"2675-2679","source":"Crossref","is-referenced-by-count":14,"title":["Two Cases of Adult-onset Still's Disease Treated with Tocilizumab that Achieved Tocilizumab-free Remission"],"prefix":"10.2169","volume":"54","author":[{"given":"Daisuke","family":"Kobayashi","sequence":"first","affiliation":[{"name":"Niigata Rheumatic Center, Japan"},{"name":"Division of Clinical Nephrology and Rheumatology, Graduate School of Medical and Dental Sciences, Niigata University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Ito","sequence":"additional","affiliation":[{"name":"Niigata Rheumatic Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Murasawa","sequence":"additional","affiliation":[{"name":"Niigata Rheumatic Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiei","family":"Narita","sequence":"additional","affiliation":[{"name":"Division of Clinical Nephrology and Rheumatology, Graduate School of Medical and Dental Sciences, Niigata University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Nakazono","sequence":"additional","affiliation":[{"name":"Niigata Rheumatic Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Bywaters EG. Still's disease in the adult. Ann Rheum Dis 30: 121-133, 1971.","DOI":"10.1136\/ard.30.2.121"},{"key":"2","unstructured":"2. Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol 19: 424-430, 1992."},{"key":"3","unstructured":"3. Fautrel B, Borget C, Rozenberg S, et al. Corticosteroid sparing effect of low dose methotrexate treatment in adult Still's disease. J Rheumatol 26: 373-378, 1999."},{"key":"4","unstructured":"4. Shojania K, Chalmers A, Rangno K. Cyclosporin A in the treatment of adult Still's disease. J Rheumatol 22: 1391-1392, 1995."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Murakami K, Fujii T, Yukawa N, et al. Successful treatment of a patient with refractory adult Still's disease by tacrolimus. Mod Rheumatol 17: 167-170, 2007.","DOI":"10.3109\/s10165-006-0559-2"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Hot A, Toh ML, Coppere B, et al. Reactive hemophagocytic syndrome in adult-onset Still disease: clinical features and long-term outcome: a case-control study of 8 patients. Medicine (Baltimore) 89: 37-46, 2010.","DOI":"10.1097\/MD.0b013e3181caf100"},{"key":"7","unstructured":"7. Hoshino T, Ohta A, Yang D, et al. Elevated serum interleukin 6, interferon-gamma, and tumor necrosis factor-alpha levels in patients with adult Still's disease. J Rheumatol 25: 396-398, 1998."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Fujii T, Nojima T, Yasuoka H, et al. Cytokine and immunogenetic profiles in Japanese patients with adult Still's disease. Association with chronic articular disease. Rheumatology (Oxford) 40: 1398-1404, 2001.","DOI":"10.1093\/rheumatology\/40.12.1398"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Chen DY, Lan JL, Lin FJ, Hsieh TY. Association of intercellular adhesion molecule-1 with clinical manifestations and interleukin-18 in patients with active, untreated adult-onset Still's disease. Arthritis Rheum 53: 320-327, 2005.","DOI":"10.1002\/art.21164"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Suematsu R, Ohta A, Matsuura E, et al. Therapeutic response of patients with adult Still's disease to biologic agents: multicenter results in Japan. Mod Rheumatol 22: 712-719, 2012.","DOI":"10.3109\/s10165-011-0569-6"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Seve P. Adult-onset Still's disease. Autoimmun Rev 13: 708-722, 2014.","DOI":"10.1016\/j.autrev.2014.01.058"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Iwamoto M, Nara H, Hirata D, Minota S, Nishimoto N, Yoshizaki K. Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease. Arthritis Rheum 46: 3388-3389, 2002.","DOI":"10.1002\/art.10620"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Puechal X, DeBandt M, Berthelot JM, et al. Tocilizumab in refractory adult Still's disease. Arthritis Care Res (Hoboken) 63: 155-159, 2011.","DOI":"10.1002\/acr.20319"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Cipriani P, Ruscitti P, Carubbi F, et al. Tocilizumab for the treatment of adult-onset Still's disease: results from a case series. Clin Rheumatol 33: 49-55, 2014.","DOI":"10.1007\/s10067-013-2381-5"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Elkayam O, Jiries N, Dranitzki Z, et al. Tocilizumab in adult-onset Still's disease: the Israeli experience. J Rheumatol 41: 244-247, 2014.","DOI":"10.3899\/jrheum.130881"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Nishina N, Kaneko Y, Kameda H, Takeuchi T. The effect of tocilizumab on preventing relapses in adult-onset Still's disease. A retrospective, single-center study. Mod Rheumatol (in press).","DOI":"10.3109\/14397595.2014.973659"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112: 3959-3964, 2008.","DOI":"10.1182\/blood-2008-05-155846"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Stern A, Riley R, Buckley L. Worsening of macrophage activation syndrome in a patient with adult onset Still's disease after initiation of etanercept therapy. J Clin Rheumatol 7: 252-256, 2001.","DOI":"10.1097\/00124743-200108000-00013"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Naniwa T, Ito R, Watanabe M, et al. Case report: successful use of short-term add-on tocilizumab for multirefractory systemic flare of adult-onset Still's disease. Clin Rheumatol 32 (Suppl 1): S103-S106, 2013.","DOI":"10.1007\/s10067-010-1562-8"},{"key":"20","unstructured":"20. Wouters JM, van de Putte LB. Adult-onset Still's disease; clinical and laboratory features, treatment and progress of 45 cases. Q J Med 61: 1055-1065, 1986."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Cush JJ, Medsger TA Jr, Christy WC, Herbert DC, Cooperstein LA. Adult-onset Still's disease. Clinical course and outcome. Arthritis Rheum 30: 186-194, 1987.","DOI":"10.1002\/art.1780300209"},{"key":"22","unstructured":"22. Ohta A, Yamaguchi M, Tsunematsu T, et al. Adult Still's disease: a multicenter survey of Japanese patients. J Rheumatol 17: 1058-1063, 1990."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Pouchot J, Sampalis JS, Beaudet F, et al. Adult Still's disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore) 70: 118-136, 1991.","DOI":"10.1097\/00005792-199103000-00004"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Asanuma YF, Mimura T, Tsuboi H, et al. Nationwide epidemiological survey of 169 patients with adult Still's disease in Japan. Mod Rheumatol (in press).","DOI":"10.3109\/14397595.2014.974881"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Nakahara H, Mima T, Yoshio-Hoshino N, Matsushita M, Hashimoto J, Nishimoto N. A case report of a patient with refractory adult-onset Still's disease who was successfully treated with tocilizumab over 6 years. Mod Rheumatol 19: 69-72, 2009.","DOI":"10.3109\/s10165-008-0116-2"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Maeshima K, Ishii K, Iwakura M. Adult-onset Still's disease with macrophage activation syndrome successfully treated with a combination of methotrexate and etanercept. Mod Rheumatol 22: 137-141, 2012.","DOI":"10.3109\/s10165-011-0477-9"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Gianella S, Schaer DJ, Schwarz U, et al. Retinal microangiopathy and rapidly fatal cerebral edema in a patient with adult-onset Still's disease and concurrent macrophage activation syndrome. Am J Hematol 83: 424-427, 2008.","DOI":"10.1002\/ajh.21084"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Kaneko K, Kaburaki M, Muraoka S, et al. Exacerbation of adult-onset Still's disease, possibly related to elevation of serum tumor necrosis factor-alpha after etanercept administration. Int J Rheum Dis 13: e67-e69, 2010.","DOI":"10.1111\/j.1756-185X.2010.01544.x"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Kobayashi M, Takahashi Y, Yamashita H, Kaneko H, Mimori A. Benefit and a possible risk of tocilizumab therapy for adult-onset Still's disease accompanied by macrophage-activation syndrome. Mod Rheumatol 21: 92-96, 2011.","DOI":"10.3109\/s10165-010-0348-9"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. de Boysson H, Fevrier J, Nicolle A, Auzary C, Geffray L. Tocilizumab in the treatment of the adult-onset Still's disease: current clinical evidence. Clin Rheumatol 32: 141-147, 2013.","DOI":"10.1007\/s10067-012-2105-2"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Bannai E, Yamashita H, Kaneko S, et al. Successful tocilizumab therapy in seven patients with refractory adult-onset Still's disease. Mod Rheumatol (in press).","DOI":"10.3109\/14397595.2014.899178"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Souabni L, Dridi L, Ben Abdelghani K, et al. Possible macrophage activation syndrome following initiation of adalimumab in a patient with adult-onset Still's disease. Pan Afr Med J 17: 94, 2014.","DOI":"10.11604\/pamj.2014.17.94.3386"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Yoshida Y, Sakamoto M, Yokota K, Sato K, Mimura T. Tocilizumab improved both clinical and laboratory manifestations except for interleukin-18 in a case of multiple drug-resistant adult-onset Still's disease. Intern Med 50: 1757-1760, 2011.","DOI":"10.2169\/internalmedicine.50.4771"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Yokota S, Imagawa T, Mori M, et al. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan. J Rheumatol 41: 759-767, 2014.","DOI":"10.3899\/jrheum.130690"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Nishida T, Suzuki K, Kuwada N, Nakamura Y, Motoyoshi K, Kamakura K. Hemophagocytic syndrome and adult Still's disease associated with meningoencephalitis and unconsciousness. Intern Med 40: 1037-1040, 2001.","DOI":"10.2169\/internalmedicine.40.1037"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Kato T, Kobayashi T, Nishino H, Hidaka Y. Double-filtration plasmapheresis for resolution of corticosteroid resistant adult onset Still's disease. Clin Rheumatol 25: 579-582, 2006.","DOI":"10.1007\/s10067-005-0030-3"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Ito T, Ozaki Y, Shimamoto K, et al. Successful treatment with plasma exchange in adult-onset Still's disease with hyper-IL-18-naemia and hyperallergic state. Mod Rheumatol 18: 407-410, 2008.","DOI":"10.3109\/s10165-008-0065-9"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Henter JI, Horne A, Arico M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48: 124-131, 2007.","DOI":"10.1002\/pbc.21039"},{"key":"39","unstructured":"39. Komiya Y, Takenaka K, Nagasaka K. Successful treatment of glucocorticoid and cyclosporine refractory adult-onset Still's disease complicated with hemophagocytic syndrome with plasma exchange therapy and tocilizumab: a case report. Nihon Rinsho Meneki Gakkai Kaishi (Jpn. J. Clin. Immunol.) 36: 478-483, 2013 (in Japanese, Abstract in English)."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/54\/20\/54_54.4935\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T21:19:31Z","timestamp":1498252771000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/54\/20\/54_54.4935\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":39,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.54.4935","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}